Psoriasis vulgaris is a chronic, multisystemic immunely mediated disease that may occur at any age. Its severity depends on hereditary and environmental factors. Although psoriasis is characterized by an epidermic proliferation, the immune system plays an important part in the evolution of the disorder.
The inflammatory process involved in psoriasis vulgaris accounts for the association of this affection with comorbidities such as: psoriatic arthritis, the metabolic syndrome, inflammatory intestinal diseases, cardiovascular affections. LyT involvement in its immunopathogenesis determines a proinflammatory status responsible for their presence. New tratments methods, aimed at the new chain links implied in the pathogenesis of psoriasis vulgaris have been lately developed.
The security profile of these agents is superior as compared to older generation medicines, but longer periods are necessary to obtain their remission. Recent studies have shown that untimely administration of antiTNα agents improves patients’ life quality and protects them against comorbidities.